Compare stocks

AGL vs RGC

vs

agilon health, inc. and Regencell Bioscience Holdings Limited Ordinary Shares

Sources and methodology ↗

Compare any two stock symbols.

1 of 3 daily views used · 2 remaining. Refreshes and chart changes do not use another view.

Daily close · 2026-11-13

Price return

Both stocks start at 0% on the first shared trading day.

AGL-86.43%
RGC1687.91%
Price return: AGL and RGCHistorical recorded observations on the same scale. Missing metrics leave gaps.-2357%5829%14016%22202%30389%202120222023202420252026

Use left and right arrow keys to inspect historical line observations. Financial bars can be focused individually.

Split-adjusted closing prices. Dividends are excluded.Year ranges begin January 1 of the end year minus the selected years.
Aurora
AURORA

Ask about these stocks.

CONTEXT ATTACHEDAGL + RGCPrices, financials and SEC filing evidence

Uses research tokens · Agent runs can use more

Similarity
Limited detail
1 shared / 2 total tags

The available classifications are too broad to identify close peers. Compare the business descriptions and filing evidence below.

How similar are their businesses?

The score compares business activities in annual filings released in 2025. Core activities receive four times the weight of material activities. Industries that fewer companies share carry more weight.

Healthcare
How we measure overlap ↗
The businesses behind the score

Industry overlap

Filing-derived business activity overlapCounts of retained positive business classifications. Circle sizes do not encode the counts or the weighted similarity score.AGL only0Shared1RGC only1

AGL only · 0

No activities in this group.

Shared activities · 1

RGC only · 1

Positive activities from the two selected annual filings. Expand each group to view all its activities, or use the complete table below. These are classification sets, not revenue shares. The weighted similarity score also accounts for exposure and how common each activity is.
Show business activity table · 2 rows, 3 columns

Core activities receive full weight; material activities receive one quarter. Select a tag to read the filing evidence.

Business activityAGLRGC
CoreCore
Not taggedMaterial

Healthcare

AGL Core

Annual filing released 2025-02-25 · GPT 6 Luna

Our model operates by primarily forming risk-bearing entities (“RBEs”) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners’ attributed patients (or global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs. Our company was formed in 2016, and we established our inaugural partnership with an anchor physician group in 2017.
Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of healthcare services for MA health plan members through our contracted physician partners and affiliated PCPs. Such fees are typically based on a defined percentage of corresponding premium that payors receive from CMS. We recognize capitation revenue over the period eligible members are entitled to receive healthcare services. Gross Profit Gross profit represents the amount earned from total revenues less medical services expense and other medical expenses. Total revenues include medical services revenue and other operating revenue. The Company’s costs of revenues consist of medical services expense and other medical expenses, which represents the costs that are directly related to providing the services that generate revenue. 56 Table of Contents
Read the annual filing ↗

RGC Core

Annual filing released 2025-10-31 · GPT 6 Luna

We conduct our business through our wholly-owned subsidiaries, Regencell Bioscience Limited, a company incorporated in Hong Kong on May 12, 2015; Regencell Limited, a company incorporated in Hong Kong on November 20, 2014 and Regencell Bioscience North America Limited, a company incorporated in the British Virgin Islands on April 25, 2022. We are an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Our goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the best natural and holistic treatment globally.
We are an early-stage bioscience company that focuses on research, development and commercialization of our standardized TCM formula for patients afflicted with neurocognitive disorders and degeneration, such as ADHD and ASD. There are two main types of medication for ADHD: stimulants such as Ritalin and Adderall and non-stimulants. For ASD, there are only two antipsychotic drugs approved by the FDA for treating irritability and aggression symptoms: risperidone and aripiprazole, according to Autism Speaks, an organization in the U.S. dedicated to promoting solutions, across the spectrum and throughout the life span. Competition
Read the annual filing ↗

Pharmaceuticals

AGL Not tagged

Annual filing released 2025-02-25 · GPT 6 Luna

This activity has no positive tag in the selected filing snapshot.

Read the annual filing ↗

RGC Material

Annual filing released 2025-10-31 · GPT 6 Luna

The TCM Practitioner has standardized the adjustable formula into a fixed formula. As a result, we have a standardized TCM formula under development targeting ADHD and ASD patients, consisting of a standard base formula and a fixed adjusted formula. We started our second efficacy trial using the standardized TCM formula in August 2021.
We completed our first research study in 2019 and started our second efficacy study in August 2021. The findings indicate show that the TCM formula can reduce ADHD and ASD symptoms. Assessment scores for all participants in our studies showed a significant decrease, suggesting that their ADHD and ASD symptoms were less severe after three months of treatment. We are developing a standardized TCM formula aimed at ADHD and ASD patients, which includes a standard base formula and a fixed adjusted formula. Our second efficacy trial using this standardized TCM formula began in August 2021. A total of twenty-eight (28) patients in Hong Kong, clinically diagnosed with ADHD and/or ASD by their healthcare professionals at varying levels of severity, voluntarily consented through their parents or guardians to participate in this trial.
Read the annual filing ↗
What each company does

Compare the businesses

agilon health, inc.

AGL · XNYS

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.

Open AGL dashboard ↗

Regencell Bioscience Holdings Limited Ordinary Shares

RGC · XNAS

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Open RGC dashboard ↗
Financial data

Fundamentals side by side

Explore financial charts ↑
Show fundamentals table · 11 rows, 3 columns
MetricAGLRGC
ExchangeXNYSXNAS
SectorHealthcareHealthcare
IndustryMedical Care FacilitiesDrug Manufacturers - Specialty & Generic
Market observation2026-11-132026-11-13
Closing price (USD)$115.66$4.94
Market cap (USD)$1.94B$2.44B
P/E (TTM)UnavailableUnavailable
Latest annual period2025-12-312026-06-30
Revenue (annual, USD)$5.93BUnavailable
Net income (annual, USD)$-391.35M$-11.70M
Gross margin (annual)UnavailableUnavailable

USD values from stored observations. Fiscal period endings and availability dates may differ.

AGL period ended 2025-12-31 · available 2026-02-25 · SEC filing ↗RGC period ended 2026-06-30 · available 2026-10-07 · SEC filing ↗
Behind the comparison

Sources and methodology

Price return uses split-adjusted daily closes and excludes dividends. Both stocks start on the first shared trading day within the selected window. Unavailable metrics leave gaps.

Financials use SEC canonical statements available by the displayed cutoff, retaining each company's fiscal period end. Annual and quarterly amounts are shown separately. P/E is unavailable when earnings do not support a positive ratio.

Business overlap uses industry tags from annual filings released in 2025. Each core activity receives full weight; each material activity receives one quarter of that weight. Rarer industries carry more weight. We sum the smaller exposure for each shared activity and divide it by the sum of the larger exposure for every activity in either company. This measures business overlap, rather than price correlation or expected returns.

Search eligibility requires distinct issuers, a shared core category and at least 20% weighted overlap, supported by industry or sector evidence and specific business activities. Broad classifications require stronger overlap within the same sector. Comparisons also need at least 252 shared price observations within two years, recent trading and a common sourced revenue or net-income trend. Missing P/E or gross margin alone does not exclude a comparison. The eligibility snapshot refreshes daily. Related comparisons use a separate, stricter peer rule; their ten-peer discovery limit does not limit search eligibility. Other stock pairs remain available in the comparison tool.

Statements available through 2026-11-16. Industry snapshot: 2025-12-31 · 5,721 classified issuers.

Opening chat…

Preparing your conversation.